Literature DB >> 27062056

The L-type Ca(2+) channel facilitates abnormal metabolic activity in the cTnI-G203S mouse model of hypertrophic cardiomyopathy.

Helena Viola1, Victoria Johnstone1, Henrietta Cserne Szappanos1, Tara Richman2, Tatiana Tsoutsman3,4, Aleksandra Filipovska2, Christopher Semsarian3,4,5, Livia Hool1,6.   

Abstract

KEY POINTS: Genetic mutations in cardiac troponin I (cTnI) are associated with development of hypertrophic cardiomyopathy characterized by myocyte remodelling, disorganization of cytoskeletal proteins and altered energy metabolism. The L-type Ca(2+) channel is the main route for calcium influx and is crucial to cardiac excitation and contraction. The channel also regulates mitochondrial function in the heart by a functional communication between the channel and mitochondria via the cytoskeletal network. We find that L-type Ca(2+) channel kinetics are altered in cTnI-G203S cardiac myocytes and that activation of the channel causes a significantly greater increase in mitochondrial membrane potential and metabolic activity in cTnI-G203S cardiac myocytes. These responses occur as a result of impaired communication between the L-type Ca(2+) channel and cytoskeletal protein F-actin, involving decreased movement of actin-myosin and block of the mitochondrial voltage-dependent anion channel, resulting in a 'hypermetabolic' mitochondrial state. We propose that L-type Ca(2+) channel antagonists, such as diltiazem, might be effective in reducing the cardiomyopathy by normalizing mitochondrial metabolic activity. ABSTRACT: Genetic mutations in cardiac troponin I (cTnI) account for 5% of families with hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy is associated with disorganization of cytoskeletal proteins and altered energy metabolism. The L-type Ca(2+) channel (ICa-L ) plays an important role in regulating mitochondrial function. This involves a functional communication between the channel and mitochondria via the cytoskeletal network. We investigate the role of ICa-L in regulating mitochondrial function in 25- to 30-week-old cardiomyopathic mice expressing the human disease-causing mutation Gly203Ser in cTnI (cTnI-G203S). The inactivation rate of ICa-L is significantly faster in cTnI-G203S myocytes [cTnI-G203S: τ1  = 40.68 ± 3.22, n = 10 vs. wild-type (wt): τ1  = 59.05 ± 6.40, n = 6, P < 0.05]. Activation of ICa-L caused a greater increase in mitochondrial membrane potential (Ψm , 29.19 ± 1.85%, n = 15 vs. wt: 18.84 ± 2.01%, n = 10, P < 0.05) and metabolic activity (24.40 ± 6.46%, n = 8 vs. wt: 9.98 ± 1.57%, n = 9, P < 0.05). The responses occurred because of impaired communication between ICa-L and F-actin, involving lack of dynamic movement of actin-myosin and block of the mitochondrial voltage-dependent anion channel. Similar responses were observed in precardiomyopathic mice. ICa-L antagonists nisoldipine and diltiazem decreased Ψm to basal levels. We conclude that the Gly203Ser mutation leads to impaired functional communication between ICa-L and mitochondria, resulting in a 'hypermetabolic' state. This might contribute to development of cTnI-G203S cardiomyopathy because the response is present in young precardiomyopathic mice. ICa-L antagonists might be effective in reducing the cardiomyopathy by altering mitochondrial function.
© 2016 The Authors. The Journal of Physiology © 2016 The Physiological Society.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27062056      PMCID: PMC4945708          DOI: 10.1113/JP271681

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  52 in total

1.  Ca2+-regulated-cAMP/PKA signaling in cardiac pacemaker cells links ATP supply to demand.

Authors:  Yael Yaniv; Magdalena Juhaszova; Alexey E Lyashkov; Harold A Spurgeon; Steven J Sollott; Edward G Lakatta
Journal:  J Mol Cell Cardiol       Date:  2011-07-28       Impact factor: 5.000

2.  Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy.

Authors:  Jens Mogensen; Ross T Murphy; Toru Kubo; Ajay Bahl; James C Moon; Ib C Klausen; Perry M Elliott; William J McKenna
Journal:  J Am Coll Cardiol       Date:  2004-12-21       Impact factor: 24.094

3.  Evidence for regulation of mitochondrial function by the L-type Ca2+ channel in ventricular myocytes.

Authors:  Helena M Viola; Peter G Arthur; Livia C Hool
Journal:  J Mol Cell Cardiol       Date:  2009-01-07       Impact factor: 5.000

4.  ATP flux is controlled by a voltage-gated channel from the mitochondrial outer membrane.

Authors:  T Rostovtseva; M Colombini
Journal:  J Biol Chem       Date:  1996-11-08       Impact factor: 5.157

Review 5.  New perspectives on the prevalence of hypertrophic cardiomyopathy.

Authors:  Christopher Semsarian; Jodie Ingles; Martin S Maron; Barry J Maron
Journal:  J Am Coll Cardiol       Date:  2015-03-31       Impact factor: 24.094

6.  Molecular insights from a novel cardiac troponin I mouse model of familial hypertrophic cardiomyopathy.

Authors:  Tatiana Tsoutsman; Jessica Chung; Alessandra Doolan; Lan Nguyen; Iwan A Williams; Emily Tu; Lien Lam; Charles G Bailey; John E J Rasko; David G Allen; Christopher Semsarian
Journal:  J Mol Cell Cardiol       Date:  2006-09-01       Impact factor: 5.000

7.  Actin filament disruption inhibits L-type Ca(2+) channel current in cultured vascular smooth muscle cells.

Authors:  M Nakamura; M Sunagawa; T Kosugi; N Sperelakis
Journal:  Am J Physiol Cell Physiol       Date:  2000-08       Impact factor: 4.249

8.  Impaired functional communication between the L-type calcium channel and mitochondria contributes to metabolic inhibition in the mdx heart.

Authors:  Helena M Viola; Abbie M Adams; Stefan M K Davies; Susan Fletcher; Aleksandra Filipovska; Livia C Hool
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-26       Impact factor: 11.205

9.  Actin structure and function: roles in mitochondrial organization and morphogenesis in budding yeast and identification of the phalloidin-binding site.

Authors:  D G Drubin; H D Jones; K F Wertman
Journal:  Mol Biol Cell       Date:  1993-12       Impact factor: 4.138

10.  Overcoming an energy crisis?: an adaptive role of glycogen synthase kinase-3 inhibition in ischemia/reperfusion.

Authors:  Peiyong Zhai; Junichi Sadoshima
Journal:  Circ Res       Date:  2008-10-24       Impact factor: 17.367

View more
  7 in total

Review 1.  The L-type Ca2+ channel: A mediator of hypertrophic cardiomyopathy.

Authors:  Helena M Viola; Livia C Hool
Journal:  Channels (Austin)       Date:  2016-07-20       Impact factor: 2.581

2.  Genetic basis and molecular biology of cardiac arrhythmias in cardiomyopathies.

Authors:  Ali J Marian; Babken Asatryan; Xander H T Wehrens
Journal:  Cardiovasc Res       Date:  2020-07-15       Impact factor: 10.787

Review 3.  Cardiac Troponin and Tropomyosin: Structural and Cellular Perspectives to Unveil the Hypertrophic Cardiomyopathy Phenotype.

Authors:  Mayra de A Marques; Guilherme A P de Oliveira
Journal:  Front Physiol       Date:  2016-09-23       Impact factor: 4.566

Review 4.  Dystrophic Cardiomyopathy-Potential Role of Calcium in Pathogenesis, Treatment and Novel Therapies.

Authors:  Victoria P A Johnstone; Helena M Viola; Livia C Hool
Journal:  Genes (Basel)       Date:  2017-03-24       Impact factor: 4.096

5.  A Morpholino Oligomer Therapy Regime That Restores Mitochondrial Function and Prevents mdx Cardiomyopathy.

Authors:  Helena M Viola; Victoria P A Johnstone; Abbie M Adams; Susan Fletcher; Livia C Hool
Journal:  JACC Basic Transl Sci       Date:  2018-06-25

Review 6.  How cytoskeletal proteins regulate mitochondrial energetics in cell physiology and diseases.

Authors:  Tanya Solomon; Megha Rajendran; Tatiana Rostovtseva; Livia Hool
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2022-10-03       Impact factor: 6.671

7.  The β2-Subunit of Voltage-Gated Calcium Channels Regulates Cardiomyocyte Hypertrophy.

Authors:  Simone Pickel; Yiliam Cruz-Garcia; Sandra Bandleon; Katalin Barkovits; Cornelia Heindl; Katharina Völker; Marco Abeßer; Kathy Pfeiffer; Alice Schaaf; Katrin Marcus; Petra Eder-Negrin; Michaela Kuhn; Erick Miranda-Laferte
Journal:  Front Cardiovasc Med       Date:  2021-07-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.